Title: Severe PeRsistent Immune Thrombocytopenic Treated with Eltrombopag (SPRITE)Summary: This study aims to assess the efficacy and safety of using Eltrombopag in patients with early refractory ITP. Early refractory ITP is defined as not responding to standard ITP therapy, including steroid, IVIG, immunosuppression within 6 months of diagnosis.Inclusion: ALL of the following criteria must be met to be eligible: Patients with ITP fulfilling […]
Sorry, you are unauthorized to view this content.
Some of our website content is restricted to Members or Subcommittees.
Please login or join us to access our 'Members only' content. Or get in touch if you are a member and believe you should have access to this content.
